Terry Heiman-Patterson, MD, Director of the Temple MDA/ALS Center of Hope, offered insight to the Associated Press for an article about NurOwn, a stem cell-based therapy for patients with ALS, or amyotrophic lateral sclerosis. At the time, the treatment was awaiting approval by the U.S. Food and Drug Administration (FDA). The FDA eventually voted against the therapy.
IMPORTANT: Beginning at 8:00 AM on September 3, Temple University Hospital – Main Campus (Broad and Ontario Streets) will no longer provide Labor and Delivery services. All childbirth services will be relocated to our new hospital location.
TRANSIT ALERT: Major cuts to bus, subway, and rail may affect travel to and from our campuses. Read full update.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH